Antibody Mediated Rejection clinical trials at UCSF

1 research study open to eligible people

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
open to eligible people ages 18-75
This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.
San Francisco, California and other locations

Last updated: October 2022